Stem definition | Drug id | CAS RN |
---|---|---|
arotinoid derivatives | 2571 | 118292-40-3 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 3.55 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 37.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 6.22 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 13, 1997 | FDA | ALLERGAN |
None
None
Source | Code | Description |
---|---|---|
ATC | D05AX05 | DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR TOPICAL USE Other antipsoriatics for topical use |
ATC | D05AX55 | DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR TOPICAL USE Other antipsoriatics for topical use |
FDA CS | M0018962 | Retinoids |
FDA EPC | N0000175607 | Retinoid |
MeSH PA | D003879 | Dermatologic Agents |
MeSH PA | D007641 | Keratolytic Agents |
MeSH PA | D009676 | Noxae |
MeSH PA | D013723 | Teratogens |
CHEBI has role | CHEBI:50176 | desquamating agent |
CHEBI has role | CHEBI:50266 | prodrugs |
CHEBI has role | CHEBI:50905 | teratogen |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Psoriasis | indication | 9014002 | DOID:8893 |
Acne vulgaris | indication | 88616000 | |
Facial Hyperpigmentation | indication | ||
Benign Facial Lentigine | indication | ||
Facial Fine Wrinkling | indication | ||
Facial Hypopigmentation | indication | ||
Sunburn | contraindication | 23346002 | |
Photosensitivity | contraindication | 90128006 | |
Pregnancy, function | contraindication | 289908002 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.17 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
0.01%;0.045% | DUOBRII | BAUSCH | N209354 | April 25, 2019 | RX | LOTION | TOPICAL | April 25, 2022 | NEW PRODUCT |
0.045% | ARAZLO | BAUSCH | N211882 | Dec. 18, 2019 | RX | LOTION | TOPICAL | Dec. 18, 2022 | NEW PRODUCT |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Retinoic acid receptor beta | Nuclear hormone receptor | AGONIST | EC50 | 9.10 | CHEMBL | CHEMBL | |||
Retinoic acid receptor alpha | Nuclear hormone receptor | AGONIST | EC50 | 7.20 | CHEMBL | CHEMBL | |||
Retinoic acid receptor gamma | Nuclear hormone receptor | AGONIST | EC50 | 7.40 | CHEMBL | CHEMBL |
ID | Source |
---|---|
4021045 | VUID |
N0000148509 | NUI |
D01132 | KEGG_DRUG |
4021045 | VANDF |
C0253908 | UMLSCUI |
CHEBI:32184 | CHEBI |
CHEMBL1657 | ChEMBL_ID |
5381 | PUBCHEM_CID |
C086827 | MESH_SUPPLEMENTAL_RECORD_UI |
7328 | INN_ID |
DB00799 | DRUGBANK_ID |
81BDR9Y8PS | UNII |
6952 | IUPHAR_LIGAND_ID |
1293452 | RXNORM |
10196 | MMSL |
190198 | MMSL |
255259 | MMSL |
5542 | MMSL |
006668 | NDDF |
108906007 | SNOMEDCT_US |
386935009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
TAZORAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-0042 | GEL | 1 mg | CUTANEOUS | NDA | 29 sections |
TAZORAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-8335 | GEL | 0.50 mg | CUTANEOUS | NDA | 29 sections |
TAZORAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-9155 | CREAM | 0.50 mg | CUTANEOUS | NDA | 26 sections |
TAZORAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-9156 | CREAM | 1 mg | CUTANEOUS | NDA | 26 sections |
TAZAROTENE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0454 | CREAM | 1 mg | TOPICAL | ANDA | 26 sections |
Tazarotene Cream | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0455 | CREAM | 1 mg | TOPICAL | ANDA | 25 sections |
Duobrii | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0187-0653 | LOTION | 0.45 mg | TOPICAL | NDA | 25 sections |
Arazlo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2098 | LOTION | 0.45 mg | TOPICAL | NDA | 24 sections |
Tazarotene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0670 | CREAM | 1 mg | TOPICAL | ANDA | 27 sections |
Tazarotene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0764 | CREAM | 1 mg | TOPICAL | ANDA | 27 sections |
Tazorac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16110-042 | GEL | 1 mg | CUTANEOUS | NDA | 29 sections |
Tazorac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16110-833 | GEL | 0.50 mg | CUTANEOUS | NDA | 29 sections |
TAZORAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16110-915 | CREAM | 0.05 mg | CUTANEOUS | NDA | 29 sections |
TAZORAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16110-916 | CREAM | 0.10 mg | CUTANEOUS | NDA | 29 sections |
Tazarotene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1373 | CREAM | 1 mg | TOPICAL | ANDA | 27 sections |
Tazarotene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1374 | CREAM | 1 mg | TOPICAL | ANDA | 27 sections |
FABIOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-295 | AEROSOL, FOAM | 1 mg | TOPICAL | NDA | 27 sections |
Tazorac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4456 | GEL | 1 mg | ORAL | NDA | 14 sections |
Tazarotene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60758-556 | CREAM | 0.50 mg | TOPICAL | NDA | 26 sections |
Tazarotene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60758-561 | CREAM | 1 mg | TOPICAL | NDA | 26 sections |
tazarotene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68308-685 | AEROSOL, FOAM | 1 mg | TOPICAL | NDA authorized generic | 29 sections |
CLINDAMYCIN 1% / NIACINULLMIDE 2% / TAZAROTENE 0.05% | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72934-1050 | GEL | 0.05 g | TOPICAL | unapproved drug other | 4 sections |
NIACINULLMIDE 4% / TAZAROTENE 0.1% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-1161 | GEL | 0.10 g | TOPICAL | unapproved drug other | 4 sections |
HYALURONIC ACID SODIUM SALT 0.5% / TAZAROTENE 0.05% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-2093 | CREAM | 0.05 g | TOPICAL | unapproved drug other | 4 sections |
HYALURONIC ACID SODIUM SALT 0.5% / TAZAROTENE 0.1% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-2094 | CREAM | 0.10 g | TOPICAL | unapproved drug other | 4 sections |
NIACINULLMIDE 4% / TAZAROTENE 0.05% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-2160 | CREAM | 0.05 g | TOPICAL | unapproved drug other | 4 sections |
NIACINULLMIDE 4% / TAZAROTENE 0.1% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-2161 | CREAM | 0.10 g | TOPICAL | unapproved drug other | 4 sections |
011312 NIACINULLMIDE 4% / TAZAROTENE 0.05% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-2208 | CREAM | 0.05 g | TOPICAL | unapproved drug other | 4 sections |